Alejandro J. Chavez on Muck Rack

Alejandro J. Chavez

Mexico City
As seen in: Nature, The Washington Post, Cell Press, Merca2.0, American Journal of Public Health, Radio Fórmula, JoVE- Journal of Visualized Experiments, The Salinas Californian, The Monterey County Herald, Nuke The Fridge and
Periodista en @mypress_mx. Escribo sobre economía, #tecnología y negocios con enfoque de actualidad.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alejandro J.

Contact Alejandro J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Fecal exfoliome sequencing captures immune dynamics of the healthy and inflamed gut - Nature Biotechnology

|
By Yiming Huang, Yiwei Sun, Chrystal F. Mavros, Lei Huang, Alejandro J. Chavez, Alejandro Chávez
| Nature
Abstract Metagenomic sequencing and metabolomics of fecal matter have revealed the impact of the gut microbiome on health and disease. In addition to microbiota, feces also contain shed or exfoliated host epithelial, secretory and immune cells, but RNA profiling of these cells is challenging owing to degradation and cross-contamination.
Open in Who Shared Issue with article?

Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir - Nature

|
By Yinkai Duan, Xiang Liu, Sho Iketani, Mengmeng Lin, Haofeng Wang, Bruce Culbertson, Hiroshi Mohri, Xiuna Yang, Yosef Sabo, Alejandro J. Chavez, Alejandro Chávez, Stephen Goff, Zihe Rao, David Ho
| Nature
Abstract Nirmatrelvir is a specific antiviral targeting the main protease (Mpro) of SARS-CoV-2, and has been approved to treat COVID-191,2. As an RNA virus characterized by high mutation rates, whether SARS-CoV-2 will develop resistance to nirmatrelvir is a concern. Our previous studies have shown that several mutational pathways confer resistance to nirmatrelvir but some result in a loss of viral replicative fitness, which in turn are compensated by additional mutations3.
Open in Who Shared Issue with article?

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir - Nature

|
By Sho Iketani, Hiroshi Mohri, Bruce Culbertson, Medini Annavajhala, Yicheng Guo, Anne-Catrin Uhlemann, Stephen Goff, Haitao Yang, Alejandro J. Chavez, Alejandro Chávez
| Nature
Abstract Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-191,2. However, as SARS-CoV-2 has evolved to become resistant to other therapeutic modalities3-9, there is a concern that the same could occur for nirmatrelvir. Here, we have examined this possibility by in vitro passaging of SARS-CoV-2 in nirmatrelvir using two independent approaches, including one on a large scale.
Open in Who Shared Issue with article?
See all 5,241 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Alejandro J.

Contact Alejandro J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified